STOCK TITAN

Avadel Pharmaceuticals plc - AVDL STOCK NEWS

Welcome to our dedicated news page for Avadel Pharmaceuticals plc (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceuticals plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avadel Pharmaceuticals plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avadel Pharmaceuticals plc's position in the market.

Rhea-AI Summary
Avadel Pharmaceuticals announces new data supporting the clinical profile of LUMRYZ for narcolepsy treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
Rhea-AI Summary
Avadel Pharmaceuticals to participate in fireside chat at Jefferies Biotech CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.88%
Tags
conferences
-
Rhea-AI Summary
Avadel Pharmaceuticals plc to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
conferences
Rhea-AI Summary
Avadel Pharmaceuticals plc (AVDL) Announces U.S. Commercial Launch of LUMRYZ™ and FDA Approval
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.89%
Tags
-
Rhea-AI Summary
Avadel Pharmaceuticals plc (Nasdaq: AVDL) approved the grant of non-statutory options to three new employees to purchase 26,000 ordinary shares under Avadel’s 2021 Inducement Plan. The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and 25% on each anniversary thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
none
Avadel Pharmaceuticals plc

Nasdaq:AVDL

AVDL Rankings

AVDL Stock Data

1.64B
66.69M
4.9%
64.09%
11.48%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Ireland
Dublin

About AVDL

avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.